General Information of the Cell Line
Cell Line ID
CL000428
Cell Line Name
JR8
Synonyms
JR 8
Category
Cancer cell line
Organism
Homo sapiens (Human)
Cellosaurus ID
CVCL_5780
Tissue Information
Lymph node
Disease
Melanoma (NCIt: C3224)
Map of Molecular Bioactivity Related to the Cell Line
Map of Molecular Bioactivity Related to the Cell Line

Cell Line
Protein
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Cell Line
Protein ID: PT01466, Telomerase reverse transcriptase
Compound ID Compound Name Compound Formula
CP0173093
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((S)-2,6-diamino-hexanoylamino)-ethyl]-amide}
   Show/Hide
C32H44N8O6
 1
1
EC50 = 800 nM
   TI
   LI
   LO
   TS
CP0173097
(S)-2-Amino-5-guanidino-pentanoic acid ({6-[2-((S)-2-amino-5-guanidino-pentanoylamino)-acetylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-methyl)-amide
   Show/Hide
C30H40N12O6
 1
1
EC50 = 800 nM
   TI
   LI
   LO
   TS
CP0255428
(S)-2-Amino-5-guanidino-pentanoic acid (2-{6-[3-((S)-2-amino-5-guanidino-pentanoylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-amide
   Show/Hide
C32H44N12O6
 1
1
EC50 = 800 nM
   TI
   LI
   LO
   TS
CP0341729
(S)-2,6-Diamino-hexanoic acid ({6-[2-((S)-2,6-diamino-hexanoylamino)-acetylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-methyl)-amide
   Show/Hide
C30H40N8O6
 1
1
EC50 = 800 nM
   TI
   LI
   LO
   TS
CP0357634
(S)-2,6-Diamino-hexanoic acid (2-{6-[3-((S)-2,6-diamino-hexanoylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-amide
   Show/Hide
C32H44N8O6
 1
1
EC50 = 800 nM
   TI
   LI
   LO
   TS
CP0067911
3-({7-[(3-ammoniopropanoyl)amino]-9,10-dioxo-9,10-dihydroanthracen-2-yl}amino)-3-oxopropan-1-aminium
   Show/Hide
C20H20N4O4
 1
1
EC50 = 1200 nM
   TI
   LI
   LO
   TS
CP0357630
9,10-Dioxo-9,10-dihydro-anthracene-2,7-dicarboxylic acid bis-{[2-((S)-2-amino-5-guanidino-pentanoylamino)-ethyl]-amide}
   Show/Hide
C32H44N12O6
 1
1
EC50 = 1200 nM
   TI
   LI
   LO
   TS
CP0214644
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((S)-2-amino-5-guanidino-pentanoylamino)-ethyl]-amide}
   Show/Hide
C32H44N12O6
 1
1
EC50 = 1500 nM
   TI
   LI
   LO
   TS
CP0253308
(S)-2,6-Diamino-hexanoic acid (2-{7-[3-((S)-2,6-diamino-hexanoylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-amide
   Show/Hide
C32H44N8O6
 1
1
EC50 = 1500 nM
   TI
   LI
   LO
   TS
CP0369410
3-({6-[(3-ammoniopropanoyl)amino]-9,10-dioxo-9,10-dihydroanthracen-2-yl}amino)-3-oxopropan-1-aminium
   Show/Hide
C20H20N4O4
 1
1
EC50 = 1500 nM
   TI
   LI
   LO
   TS
CP0319421
9,10-Dioxo-9,10-dihydro-anthracene-2,7-dicarboxylic acid bis-{[2-((S)-2,6-diamino-hexanoylamino)-ethyl]-amide}
   Show/Hide
C32H44N8O6
 1
1
EC50 = 3000 nM
   TI
   LI
   LO
   TS
CP0214645
(S)-2-Amino-5-guanidino-pentanoic acid (2-{7-[3-((S)-2-amino-5-guanidino-pentanoylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-amide
   Show/Hide
C32H44N12O6
 1
1
EC50 = 4000 nM
   TI
   LI
   LO
   TS
CP0214649
2-Amino-N-({6-[2-(2-amino-acetylamino)-acetylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-methyl)-acetamide
   Show/Hide
C22H22N6O6
 1
1
EC50 = 5000 nM
   TI
   LI
   LO
   TS
CP0334240
2-{[(6-{[(2-ammonioethyl)amino]carbonyl}-9,10-dioxo-9,10-dihydroanthracen-2-yl)carbonyl]amino}ethanaminium
   Show/Hide
C20H20N4O4
 1
1
EC50 = 5000 nM
   TI
   LI
   LO
   TS
CP0252909
(2S)-N-[2-[[9,10-dioxo-6-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]anthracen-2-yl]amino]-2-oxoethyl]pyrrolidine-2-carboxamide
   Show/Hide
C28H30N6O6
 1
1
EC50 = 10000 nM
   TI
   LI
   LO
   TS
CP0214643
2-{[(7-{[(2-ammonioethyl)amino]carbonyl}-9,10-dioxo-9,10-dihydroanthracen-2-yl)carbonyl]amino}ethanaminium
   Show/Hide
C20H20N4O4
 1
1
EC50 = 15000 nM
   TI
   LI
   LO
   TS
CP0214646
(S)-2-Amino-N-(2-{7-[3-((S)-2-amino-propionylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-propionamide
   Show/Hide
C26H30N6O6
 1
1
EC50 = 15000 nM
   TI
   LI
   LO
   TS
CP0327296
(S)-2-Amino-N-({6-[2-((S)-2-amino-propionylamino)-acetylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-methyl)-propionamide
   Show/Hide
C24H26N6O6
 1
1
EC50 = 25000 nM
   TI
   LI
   LO
   TS
CP0341721
2-Amino-N-[6-(2-amino-acetylamino)-9,10-dioxo-9,10-dihydro-anthracen-2-yl]-acetamide
   Show/Hide
C18H16N4O4
 1
1
EC50 = 25000 nM
   TI
   LI
   LO
   TS
CP0350694
(2S,3S)-2-Amino-3-methyl-pentanoic acid ({6-[2-((2S,3S)-2-amino-3-methyl-pentanoylamino)-acetylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-methyl)-amide
   Show/Hide
C30H38N6O6
 1
1
EC50 = 25000 nM
   TI
   LI
   LO
   TS
CP0067909
(2S)-2-amino-N-(2-{[7-({2-[(2S)-2-amino-3-hydroxypropanamido]ethyl}carbamoyl)-9,10-dioxo-9,10-dihydroanthracen-2-yl]formamido}ethyl)-3-hydroxypropanamide
   Show/Hide
C26H30N6O8
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0067910
9,10-Dioxo-9,10-dihydro-anthracene-2,7-dicarboxylic acid bis-{[2-((S)-2-amino-propionylamino)-ethyl]-amide}
   Show/Hide
C26H30N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0166865
(S)-2-Amino-N-(2-{6-[3-((S)-2-amino-3-methyl-butyrylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-3-methyl-butyramide
   Show/Hide
C30H38N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0173092
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((2S,3S)-2-amino-3-methyl-pentanoylamino)-ethyl]-amide}
   Show/Hide
C32H42N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0173094
(2S,3S)-2-Amino-3-methyl-pentanoic acid (2-{7-[3-((2S,3S)-2-amino-3-methyl-pentanoylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-amide
   Show/Hide
C32H42N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0173095
(S)-2-Amino-N-(2-{7-[3-((S)-2-amino-3-phenyl-propionylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-3-phenyl-propionamide
   Show/Hide
C38H38N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0173096
(S)-2-Amino-N-(2-{6-[3-((S)-2-amino-propionylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-propionamide
   Show/Hide
C26H30N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0214642
9,10-Dioxo-9,10-dihydro-anthracene-2,7-dicarboxylic acid bis-{[2-((S)-2-amino-3-phenyl-propionylamino)-ethyl]-amide}
   Show/Hide
C38H38N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0214647
(2S,3S)-2-Amino-3-methyl-pentanoic acid (2-{6-[3-((2S,3S)-2-amino-3-methyl-pentanoylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-amide
   Show/Hide
C32H42N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0234908
9,10-Dioxo-9,10-dihydro-anthracene-2,7-dicarboxylic acid bis-{[2-((2S,3S)-2-amino-3-methyl-pentanoylamino)-ethyl]-amide}
   Show/Hide
C32H42N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0291140
9,10-Dioxo-9,10-dihydro-anthracene-2,7-dicarboxylic acid bis-{[2-(2-amino-acetylamino)-ethyl]-amide}
   Show/Hide
C24H26N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0291141
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((S)-2-amino-3-hydroxy-propionylamino)-ethyl]-amide}
   Show/Hide
C26H30N6O8
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0334239
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((S)-2-amino-3-phenyl-propionylamino)-ethyl]-amide}
   Show/Hide
C38H38N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0339884
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((S)-2-amino-4-methyl-pentanoylamino)-ethyl]-amide}
   Show/Hide
C32H42N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0344871
(S)-2-Amino-N-({6-[2-((S)-2-amino-3-methyl-butyrylamino)-acetylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-methyl)-3-methyl-butyramide
   Show/Hide
C28H34N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0347295
(S)-2-Amino-N-({6-[2-((S)-2-amino-3-phenyl-propionylamino)-acetylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-methyl)-3-phenyl-propionamide
   Show/Hide
C36H34N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0352063
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((S)-2-amino-propionylamino)-ethyl]-amide}
   Show/Hide
C26H30N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0357627
(2S,3R)-2-amino-N-(2-{[7-({2-[(2S,3R)-2-amino-3-hydroxybutanamido]ethyl}carbamoyl)-9,10-dioxo-9,10-dihydroanthracen-2-yl]formamido}ethyl)-3-hydroxybutanamide
   Show/Hide
C28H34N6O8
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0359289
9,10-Dioxo-9,10-dihydro-anthracene-2,7-dicarboxylic acid bis-{[2-((S)-2-amino-4-methyl-pentanoylamino)-ethyl]-amide}
   Show/Hide
C32H42N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0359290
(2S)-2-amino-N-[2-[[6-[[2-[[(2S)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-9,10-dioxoanthracen-2-yl]amino]-2-oxoethyl]-4-methylpentanamide
   Show/Hide
C30H38N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0368103
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-(2-amino-acetylamino)-ethyl]-amide}
   Show/Hide
C24H26N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0371198
9,10-Dioxo-9,10-dihydro-anthracene-2,6-dicarboxylic acid bis-{[2-((2S,3R)-2-amino-3-hydroxy-butyrylamino)-ethyl]-amide}
   Show/Hide
C28H34N6O8
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
CP0525959
(S)-2-Amino-N-(2-{6-[3-((S)-2-amino-3-phenyl-propionylamino)-propionylamino]-9,10-dioxo-9,10-dihydro-anthracen-2-ylcarbamoyl}-ethyl)-3-phenyl-propionamide
   Show/Hide
C38H38N6O6
 1
1
EC50 > 40000 nM
   TI
   LI
   LO
   TS
Protein family and CMB statistics Related to the Cell Line
Cell Lines Derived from the same Tissue Source (Lymph node)
Cell Line Name Organism Disease
AN3-CA Homo sapiens (Human) Acanthosis nigricans--NCIt; C7359; Endometrial adenocarcinoma
A2058 Homo sapiens (Human) Amelanotic melanoma
LOX-IMVI Homo sapiens (Human) Amelanotic melanoma
SW620 Homo sapiens (Human) Colon adenocarcinoma
SW620/AD300 Homo sapiens (Human) Colon adenocarcinoma
LoVo Homo sapiens (Human) Colon adenocarcinoma
SK-MEL-5 Homo sapiens (Human) Cutaneous melanoma
SU-DHL-5 Homo sapiens (Human) Diffuse large B-cell lymphoma germinal center B-cell type
HOC313 Homo sapiens (Human) Floor of mouth squamous cell carcinoma
HGC-27 Homo sapiens (Human) Gastric carcinoma
NUGC-4 Homo sapiens (Human) Gastric signet ring cell adenocarcinoma
NCI-H1993 Homo sapiens (Human) Lung adenocarcinoma
PC-9 Homo sapiens (Human) Lung adenocarcinoma
NCI-H838 Homo sapiens (Human) Lung adenocarcinoma
NCI-H1568 Homo sapiens (Human) Lung adenocarcinoma
PC9-DRH Homo sapiens (Human) Lung adenocarcinoma
NCI-H2009 Homo sapiens (Human) Lung adenocarcinoma
NCI-H1299 Homo sapiens (Human) Lung large cell carcinoma
NCI-H1155 Homo sapiens (Human) Lung large cell carcinoma
NCI-H292 Homo sapiens (Human) Lung mucoepidermoid carcinoma
HBL-2 [Human mantle cell lymphoma] Homo sapiens (Human) Mantle cell lymphoma
MNT-1 Homo sapiens (Human) Melanoma
MM96L Homo sapiens (Human) Melanoma
WM3629 Homo sapiens (Human) Melanoma
L3.6pl Homo sapiens (Human) Pancreatic adenosquamous carcinoma
LNCaP Homo sapiens (Human) Prostate carcinoma
LAPC-4 Homo sapiens (Human) Prostate carcinoma
LNCaP-AR Homo sapiens (Human) Prostate carcinoma
LNCaP C4-2 Homo sapiens (Human) Prostate carcinoma
MR49F Homo sapiens (Human) Prostate carcinoma
LNCaP-hr Homo sapiens (Human) Prostate carcinoma
LNCap-ARR2PB-eGFP Homo sapiens (Human) Prostate carcinoma
Th17 Mus musculus (Mouse) -